Eidos Therapeutics (NASDAQ:EIDX) released its quarterly earnings data on Tuesday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.02), Fidelity Earnings reports.
Eidos Therapeutics stock opened at $12.91 on Thursday. Eidos Therapeutics has a 12 month low of $8.89 and a 12 month high of $24.75.
Several research firms have issued reports on EIDX. Roth Capital began coverage on Eidos Therapeutics in a research note on Wednesday, October 31st. They issued a “buy” rating and a $28.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on Eidos Therapeutics in a research note on Monday, July 16th. They issued an “overweight” rating and a $36.00 price objective on the stock. Zacks Investment Research raised Eidos Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 8th. Bank of America decreased their target price on Eidos Therapeutics from $24.00 to $13.00 and set a “neutral” rating on the stock in a research report on Monday, October 1st. Finally, Barclays assumed coverage on Eidos Therapeutics in a research report on Monday, July 16th. They issued an “overweight” rating and a $32.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $27.25.
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Featured Article: Yield Curve
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.